1,2-dipalmitoylphosphatidylcholine has been researched along with Cancer of Ovary in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chang, S; Liu, L; Sun, J; Wang, Z; Xu, RX; Yin, M; Zhu, S; Zhu, Y | 1 |
| Chiu, GNC; Liu, Y; Ng, Y; Toh, MR | 1 |
2 other study(ies) available for 1,2-dipalmitoylphosphatidylcholine and Cancer of Ovary
| Article | Year |
|---|---|
Ultrasound-mediated destruction of oxygen and paclitaxel loaded lipid microbubbles for combination therapy in hypoxic ovarian cancer cells.
Topics: 1,2-Dipalmitoylphosphatidylcholine; Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Hypoxia; Cell Line, Tumor; Cell Survival; Combined Modality Therapy; Drug Carriers; Drug Liberation; Female; Gene Expression Regulation, Neoplastic; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Microbubbles; Ovarian Neoplasms; Oxygen; Paclitaxel; Phosphatidylethanolamines; Ultrasonic Waves | 2016 |
Lipid-dendrimer hybrid nanosystem as a novel delivery system for paclitaxel to treat ovarian cancer.
Topics: 1,2-Dipalmitoylphosphatidylcholine; Animals; Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Cell Survival; Dendrimers; Dose-Response Relationship, Drug; Drug Carriers; Drug Compounding; Female; Humans; Mice, SCID; Nanoparticles; Nanotechnology; Nylons; Ovarian Neoplasms; Paclitaxel; Solubility; Time Factors; Xenograft Model Antitumor Assays | 2015 |